US Peptide Regulation in 2026: What Changed and What Is Pending

FDA and Congress | 2026-10-04 | Regulatory update

Several US developments in 2026 bear on how peptides are regulated: FDA statements on compounded weight-management drugs, an advisory committee vote on peptides for compounding, revised draft guidances for generic peptide drugs, warning letters to online sellers, and a bill in Congress. This summary restates the public record, with a source for each point.

What happened

Compounded weight-management drugs (6 February 2026)

According to an FDA statement of 6 February 2026, the agency announced its intent to restrict active pharmaceutical ingredients for certain prescription weight-management drugs that are intended for use in non-FDA-approved compounded products mass-marketed as similar alternatives to FDA-approved drugs. The statement also said FDA is taking steps against misleading direct-to-consumer marketing following warning letters sent in the fall of 2025, and that companies cannot claim that non-FDA-approved compounded products are generic versions of, or the same as, FDA-approved drugs (FDA, 6 February 2026).

Advisory committee vote on peptides for compounding (23-24 July 2026)

FDA's Pharmacy Compounding Advisory Committee voted, by margins from 7-4 to 8-6, to recommend adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the list of bulk drug substances that may be used in compounding under Section 503A, and voted against emideltide. According to a law-firm analysis, the votes ran counter to the recommendation of FDA's scientific review team, are advisory only, and do not themselves add any substance to the list; adding a substance requires notice-and-comment rulemaking (Bass, Berry & Sims, 31 July 2026). Reuters reported on 15 September 2026 that FDA had previously restricted compounding of BPC-157, citing what it described as significant safety risks and insufficient human data, and that FDA had not yet issued its decision (Reuters via Medscape).

Revised draft guidances for generic peptide drugs (comments due 28 September 2026)

A Federal Register notice published on 29 July 2026 announced revised draft product-specific guidances on the design of bioequivalence studies to support abbreviated new drug applications. The active ingredients listed include calcitonin salmon, glucagon and teriparatide, along with three prescription peptide medicines. Comments were requested by 28 September 2026. The same notice withdrew FDA's May 2021 guidance on abbreviated applications for certain highly purified synthetic peptide drug products, which FDA said it plans to revise and reissue this year (Federal Register, 91 FR 47834).

Warning letters to online peptide sellers (August 2026)

FDA issued warning letters in August 2026 to five online sellers of peptide products, according to a law-firm analysis (McDermott Will & Schulte, 24 September 2026). In one letter, FDA stated that despite "for research use only" statements on the seller's labeling, evidence from its website established that the products were intended to be drugs for human use, and cited them as unapproved new drugs (FDA warning letter, 24 August 2026).

PEPTIDES for Veterans Act (September 2026)

Rep. Nancy Mace introduced H.R. 10212, the PEPTIDES for Veterans Act, on 1 September 2026, and it was referred to the House Committee on Veterans' Affairs (Congress.gov). According to Stars and Stripes, the bill would direct the Department of Veterans Affairs to review current peptide regulations, report its definitions of "peptide" and "peptide-based therapy" to Congress within six months, and conduct an 18-month study; a five-year pilot would follow only if the initial findings are positive (Stars and Stripes, 28 September 2026).

Key details from the sources

• Issuing bodies: FDA; FDA Pharmacy Compounding Advisory Committee; U.S. House of Representatives
• Documents: FDA statement (2026-02-06); advisory committee votes (2026-07-23 and 2026-07-24); Federal Register notice 91 FR 47834 (2026-07-29); FDA warning letters (August 2026); H.R. 10212 (2026-09-01)
• Comment deadline: 2026-09-28 for the revised draft generic peptide guidances
• Substances named: prescription weight-management drugs; three prescription peptide medicines; BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and emideltide in the advisory committee review

What the documents say about research-material status

None of these documents creates a category for research materials. The advisory committee votes did not change the regulatory status of any peptide (Bass, Berry & Sims). In the August 2026 warning letter, FDA treated "research use only" statements as outweighed by other evidence of intended human use on the seller's website (FDA warning letter).

What remains open

• FDA's decision on the advisory committee recommendations; any addition to the 503A list requires notice-and-comment rulemaking (Bass, Berry & Sims).
• A follow-on advisory committee meeting, which FDA has said it will schedule before the end of February 2027, to review further peptides including GHK-Cu (Bass, Berry & Sims).
• Final versions of the revised generic peptide guidances, and the reissued peptide guidance FDA plans this year (Federal Register).
• H.R. 10212 remains at the committee stage (Congress.gov).

Frequently asked questions

Did the July 2026 advisory committee vote allow compounding of BPC-157?

No. The votes are advisory recommendations. FDA keeps final authority, and adding a substance to the 503A list requires notice-and-comment rulemaking.

What did the July 2026 Federal Register notice cover?

It announced revised draft guidances on bioequivalence study design for generic versions of several peptide drugs, with comments requested by 28 September 2026.

Has the PEPTIDES for Veterans Act become law?

No. The bill was introduced on 1 September 2026 and was referred to the House Committee on Veterans' Affairs.

Sources

• U.S. FDA (press announcement) | 2026-02-06 | www.fda.gov
• Bass, Berry & Sims (analysis) | 2026-07-31 | bassberry.com
• Reuters via Medscape | 2026-09-15 | www.medscape.com
• Federal Register (FDA notice, 91 FR 47834) | 2026-07-29 | www.federalregister.gov
• U.S. FDA (warning letter, 2026-08-24) | 2026-08-24 | www.fda.gov
• McDermott Will & Schulte (client alert) | 2026-09-24 | www.mcdermottlaw.com
• Congress.gov, H.R. 10212 | 2026-09-01 | www.congress.gov
• Stars and Stripes | 2026-09-28 | www.stripes.com

BioLabs Research has no affiliation with, and no endorsement from, any person named in this article.

This article is a summary of publicly reported information for research-community awareness only. It is not medical advice, not legal advice, and not a statement about any BioLabs Research product.

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

This summary is for research-community awareness only and is not legal advice.